share_log

Roth MKM Initiates Coverage On Immix Biopharma With Buy Rating, Announces Price Target of $14

Roth MKM Initiates Coverage On Immix Biopharma With Buy Rating, Announces Price Target of $14

羅斯 MKM 以購買評級啟動 Immix 生物製藥的覆蓋範圍,宣布目標價格為 14 美元
Benzinga Real-time News ·  2023/02/22 08:21

Roth MKM analyst Jonathan Aschoff initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a Buy rating and announces Price Target of $14.

Roth MKM分析師Jonathan Aschoff在ImMix Biophma(納斯達克:IMMX)上以買入評級啟動報道,並宣佈目標價為14美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論